IMHO I think what Pha has implicitly pointed out is that you may have bent over far too backwards to paint this release in at least some negative light. IMO. you can find concerns and flaws in many many trials on any number of indicators and markers, heck some drugs and treatments get approved despite having serious negative effects (jakafi anyone?), but you are very insistent to point out the uncertainty of hypertension on a two person trial? (can you even call this a trial?)
just out of interest, going through the sr-agvhd data and trials, what were your concerns around hypertention on those trials? and why is this your concern here when they are essentially the same treatment (albeit the dosage and timing(s) differed)?
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-212
-
- There are more pages in this discussion • 212 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.030(3.13%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | $1.03 | 96.5¢ | $4.704M | 4.708M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 87395 | 98.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 274051 | 2 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |